Cryoport, Inc. (NASDAQ:CYRX) CFO Robert Stefanovich Sells 1,079 Shares

Cryoport, Inc. (NASDAQ:CYRXGet Free Report) CFO Robert Stefanovich sold 1,079 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $17.54, for a total transaction of $18,925.66. Following the sale, the chief financial officer now directly owns 128,333 shares of the company’s stock, valued at $2,250,960.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Robert Stefanovich also recently made the following trade(s):

  • On Friday, March 15th, Robert Stefanovich sold 1,035 shares of Cryoport stock. The stock was sold at an average price of $15.43, for a total transaction of $15,970.05.
  • On Monday, March 11th, Robert Stefanovich sold 1,119 shares of Cryoport stock. The stock was sold at an average price of $16.35, for a total transaction of $18,295.65.

Cryoport Stock Performance

Shares of CYRX opened at $18.12 on Thursday. Cryoport, Inc. has a 12 month low of $9.00 and a 12 month high of $24.30. The firm has a fifty day simple moving average of $15.95 and a 200 day simple moving average of $14.37. The stock has a market capitalization of $887.52 million, a price-to-earnings ratio of -8.24 and a beta of 1.61. The company has a current ratio of 11.73, a quick ratio of 11.16 and a debt-to-equity ratio of 0.82.

Wall Street Analyst Weigh In

Several brokerages have commented on CYRX. Stephens reaffirmed an “equal weight” rating and issued a $17.00 target price on shares of Cryoport in a research note on Wednesday, March 13th. Needham & Company LLC lowered their target price on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, March 13th. Finally, UBS Group upped their target price on shares of Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a research note on Friday, March 15th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Cryoport has a consensus rating of “Hold” and a consensus price target of $18.29.

Get Our Latest Analysis on Cryoport

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CYRX. Tower Research Capital LLC TRC boosted its holdings in Cryoport by 228.5% during the second quarter. Tower Research Capital LLC TRC now owns 2,060 shares of the company’s stock worth $36,000 after purchasing an additional 1,433 shares during the last quarter. Quarry LP acquired a new position in Cryoport during the second quarter worth $40,000. State of Wyoming boosted its holdings in Cryoport by 42.7% during the fourth quarter. State of Wyoming now owns 3,026 shares of the company’s stock worth $53,000 after purchasing an additional 905 shares during the last quarter. Comerica Bank acquired a new position in Cryoport during the third quarter worth $53,000. Finally, Natixis Investment Managers International boosted its holdings in Cryoport by 61.5% during the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock worth $70,000 after purchasing an additional 1,727 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Company Profile

(Get Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Recommended Stories

Insider Buying and Selling by Quarter for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.